Variant · Expression
SLC12A2 OVEREXPRESSION
CI-VAR-00003047Explore in graph →CIViC 3829
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29431617
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Glioblastoma1 | ||||||||
| SLC12A2 OVEREXPRESSION | Antisecretory Factor-enriched Egg Yolk Powder Supplement + TemozolomideCombination | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12689Antisecretory factor (AF) induction by the SPC diet or Salovum in GBM xenografts (GBM43, GBM6) reduced NKCC1-mediated chloride influx, chloride permeability, and blocked regulatory volume increase in … (full text at CIViC) PMID 29431617 · Ilkhanizadeh et al., 2018 · Open in CIViC | civic |
| Unmapped disease1unmapped disease | ||||||||
| SLC12A2 OVEREXPRESSION | (functional) | Functional | D | Supports Gain Of Function | 2 | submitted | EID12683Bumetanide directly inhibits NKCC1 (SLC12A2) with an IC50 of 0.16–0.28 μM in hNKCC1-transfected HEK293 cells, which is substantially more potent than the NKCC1 inhibitor ARN23746 (IC50 ~20 μM) and STS… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available